Evidence map›Paper›PMID 41193701›Full record

ReviewHypertension research : official journal of the Japanese Society of Hypertension2026

Doxazosin GITS (gastrointestinal therapeutic system) is an actor to consider in the control of hypertension. A narrative review.

Miguel Camafort, Hae-Young Lee, Hung-Yu Chang, Bancha Satirapoj, Kazuomi Kario

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Miguel CamafortHypertension Unit, Department of Internal Medicine, Hospital Clinic, University of Barcelona, Barcelona, Spain. camafort@clinic.cat.ORCID 0000-0002-8669-6410
Hae-Young LeeDivision of Cardiology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.ORCID 0000-0002-9521-4102
Hung-Yu ChangHeart Center, Cheng Hsin General Hospital, Taipei, Taiwan.ORCID 0000-0003-1219-7739
Bancha SatirapojDivision of Nephrology Department of Medicine, Phramongkutklao hospital and College of Medicine, Bangkok, Thailand.ORCID 0000-0002-8881-0942
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine (JMU), Tochigi, Japan.ORCID 0000-0002-8251-4480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension remains a leading global cause of cardiovascular morbidity and mortality, yet blood pressure control rates remain suboptimal despite advances in antihypertensive therapy. Multiple barriers-including cost, side effects, therapeutic complexity, and physician inertia-impede effective management, particularly in aging populations and low-resource settings. This review evaluates the therapeutic role of doxazosin, particularly in its extended-release gastrointestinal therapeutic system formulation, as a potential adjunct in contemporary hypertension treatment, including resistant hypertension.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAntihypertensive AgentsDoxazosinHypertensionBlood PressureHumansAdrenergic alpha-1 Receptor AntagonistsAntihypertensive AgentsDoxazosinDigital hypertensionImplemental hypertensionMorning hypertension

Identifiers

PMID41193701
PMCPMC12960196

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.